Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TCR repertoire changes after standardized IV methylprednisolone treatment in Graves' ophthalmopathy
ChiCTR-OPB-15006526Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Xi'an Jiaotong University
- Start
- Jul 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of methylprednisolone in Graves' ophthalmopathy (TED), sponsored by First Affiliated Hospital of Xi'an Jiaotong University. Primary endpoint: T-cell receptor repertoire. Started Jul 2015; status: recruiting.
02
Drugs
methylprednisolone
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on ChiCTR-OPB-15006526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-OPB-15006526.